Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Senti Biosciences
company
About
Senti Biosciences is a developer of a programmable biology platform for cancer therapies.
- 51 - 100
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $105M
- Industries
- Biotechnology,Health Care,Medical,Therapeutics
- Founded date
- Jan 1, 2016
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Senti Biosciences is a developer of a programmable biology platform for cancer therapies. Its therapeutics specialize in cell engineering and biological programming to build the future of gene and cell-based therapies that enable physicians to give patients life-saving treatments at an affordable cost.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
3
$158.22M
Senti Biosciences has raised a total of
$158.22M
in funding over 2 rounds. Their latest funding was raised on
Jan 6, 2021 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jan 6, 2021 | Series B | $105M | 1 | — | — | Detail |
| Feb 27, 2018 | Series A | $53M | 2 | — | — | Detail |
| Dec 19, 2017 | Grant | $225K | 1 |
National Science Foundation
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
4
Senti Biosciences is funded by 4 investors.
National Science Foundation
and Gaingels
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
National Science Foundation
|
Yes | Grant |
Gaingels
|
— | Series B |
Goodman Capital
|
— | Series A |
Allen & Company
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
